Opinion|Videos|August 12, 2024
ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What future research is needed to further support decision-making when using CDK4/6 inhibitors for early breast cancer?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
2
Experts Warn CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust
3
New Dermatologic Therapies Make Waves at Maui Derm 2026
4
Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations
5
